This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

June 14-16, 2022
Intercontinental Mark Hopkins HotelSan Francisco, California

Hanspeter Gerber
CSO & SVP at 3T Biosciences


Hans-Peter has over 25 years of R&D experience in oncology, including antibody-drug conjugates (ADCs), redirected T-cell targeting (bispecifics) and adoptive T-cell therapies. He built highly successful drug development teams in pharma, biotech and startup companies and oversaw the development and filings of over 10 INDs and contributed to 3 BLAs, including Avastin and two ADCs (Mylotarg, Besponsa). Hans-Peter is currently CSO at 3T Biosciences where he oversees target ID, platform- and preclinical program development of TCR-T cell and CD3-bispecific programs. He is an author on over 100 peer-reviewed papers in high impact journals in the field of oncology drug discovery.

Agenda Sessions

  • 3T Case Study - Identification of Novel Targets for the Treatment of Solid Tumours in Broad Patient Populations

  • Speaker Q&A